Immune-Onc Therapeutics
Science at Our Core. Patients in Our Hearts.
14 employees · est. 2016 · Palo Alto, United States
Cantargia AB is the older company (2010 vs 2016).
Side-by-Side Comparison
| Metric | Cantargia AB | Immune-Onc Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2010 older | 2016 |
| Headquarters | ||
| Headquarters | Lund, Sweden | Palo Alto, United States |
| Employees | ||
| Employees | 32 | 14 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness, Medical Devices | Not tracked yet |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series B |
| Total Funding | ||
| Total Funding | $257.00M | $140.14M |
| Funding Rounds | ||
| Funding Rounds | 2 | 6 |
| Services | ||
| Services | Not tracked yet | Development of novel immunotherapies, Targeting myeloid cell surface proteins, Research and drug development collaborations |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with blood cancers, Patients with solid tumors, Individuals with autoimmune or inflammatory diseases, Healthcare professionals |
| Taxonomy | ||
| Taxonomy | Antibody-based Therapies, Clinical Programs, IL1RAP, Cancer Treatment, Autoimmune Diseases, Inflammatory Diseases, Leukemic Stem Cells, Hematopoietic Stem Cells, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Antibody-based Therapy, Swedish Listed Company, Phase II Development | Oncology, Biotherapeutics, Myeloid Cell Inhibitory Receptors, Leukocyte Immunoglobulin-Like Receptor B (LILRB), Antagonist Antibodies, Clinical-Stage Development, Immuno-Oncology, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Solid Tumors, LAIR1, Bispecific Antibody, Drug Development, Cancer Treatment |
| Website | ||
| Website | cantargia.com | immune-onc.com |
About Cantargia AB
Cantargia is a Swedish listed biotechnology company that focuses on developing antibody-based therapies targeting IL1RAP. The company's clinical programs include nadunolimab, which is currently in phase II development for the treatment of cancer, and CAN10 in phase I development for autoimmune/infla...
About Immune-Onc Therapeutics
Immune-Onc Therapeutics is a private, clinical-stage biotechnology company, founded in 2016, and based in Palo Alto, California. With a commitment encapsulated by its slogan, "Science at Our Core. Patients in Our Hearts," the company is focused on developing novel biotherapeutics targeting myeloid c...
We will tell you when either one moves
BounceWatch watches Cantargia AB and Immune-Onc Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Cantargia AB and Immune-Onc Therapeutic... — by email.
Frequently Asked Questions
Compare Cantargia AB with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Cantargia AB on 12 Sep 2024, and Immune-Onc Therapeutics on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
